Table 2 Comparison of cardiac computed tomography findings between subjects with and without metabolic syndrome (MS)
| Â | MS | Non-MS | P |
|---|---|---|---|
Baseline data | |||
 CACS | n = 825 | n = 1601 |  |
  Initial CACS, median (IQR) | 11.1 (0‒98.5) | 0.0 (0‒43.0) | <0.001a |
  Prevalence of coronary calcification, n (%) | 449 (54.4) | 734 (45.8) | <0.001 |
 CCTA | n = 381 | n = 698 |  |
  Significant stenosis, n (%) | 52 (13.6) | 62 (8.9) | 0.017 |
  Multivessel disease, n (%) | 16 (4.2) | 12 (1.7) | 0.025 |
  Any plaque, n (%) | 210 (55.1) | 302 (43.3) | <0.001 |
Plaque type | |||
 Calcified, n (%) | 156 (40.9) | 233 (33.4) | 0.463 |
 Mixed, n (%) | 60 (15.7) | 82 (11.7) | 0.764 |
 Non-calcified, n (%) | 41 (10.8) | 63 (9.0) | 0.739 |
Follow up data | |||
 CACS | n = 825 | n = 1601 |  |
  FU interval, median (IQR), days | 1285 (763.3‒1640.3) | 1292 (763.5‒1703.0) | 0.808 |
  Follow-up CACS, median (IQR) | 45.3 (0‒225.3) | 10.4 (0‒115.4) | <0.001a |
  Progression of CACS, n (%) | 434 (52.6) | 647 (40.4) | <0.001 |
 CCTA | n = 381 | n = 698 |  |
  FU interval, median (IQR), days | 1106 (735.0‒1484.6) | 1102 (741.8‒1465.3) | 0.948 |
  Progression of stenosis, n (%) | 109 (28.6) | 163 (23.4) | 0.067 |
  Development of vulnerable plaque, n (%) | 95 (24.9) | 138 (19.8) | 0.053 |